Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2015 Jul 9.
Published in final edited form as: Chemistry. 2014 Apr 8;20(21):6444–6454. doi: 10.1002/chem.201400024

Two-Step Functionalization of Oligosaccharides Using Glycosyl Iodide and Trimethylene Oxide and Its Applications to Multivalent Glycoconjugates

Hsiao-Wu Hsieh 1, Ryan A Davis 1, Jessica A Hoch 1, Jacquelyn Gervay-Hague 1,
PMCID: PMC4497529  NIHMSID: NIHMS703066  PMID: 24715520

Abstract

Oligosaccharide conjugates, such as glycoproteins and glycolipids, are potential chemotherapeutics and also serve as useful tools for understanding the biological roles of carbohydrates. With many modern isolation and synthetic technologies providing access to a wide variety of free sugars, there is increasing need for general methodologies for carbohydrate functionalization. Herein, we report a two-step methodology for the conjugation of per-O-acetylated oligosaccharides to functionalized linkers that can be used for various displays. Oligosaccharides obtained from both synthetic and commercial sources were converted to glycosyl iodides and activated with I2 to form reactive donors that were subsequently trapped with trimethylene oxide to form iodopropyl conjugates in a single step. The terminal iodide served as a chemical handle for further modification. Conversion into the corresponding azide followed by copper-catalyzed azide–alkyne cycloaddition afforded multivalent glycoconjugates of Gb3 for further investigation as anti-cancer therapeutics.

Keywords: carbohydrates, functionalization, glycosylation, glycosyl iodides, multivalent glycoconjugates

Introduction

Glycosylation is one of the most abundant post-translational modifications in eukaryotic cells, leading to structurally diverse biomolecules that mediate cellular interactions in processes ranging from cancer progression to immune response.[1] With no corresponding genetic code and a plethora of possible structures,[2] understanding the functions of complex oligosaccharides, as well as isolating them from natural resources, is challenging. Obtaining sufficient amounts of pure and homogenous oligosaccharides[3] and further modifying isolated oligosaccharides typically requires multiple synthetic steps and purifications. These difficulties have directed research efforts toward the chemical synthesis of oligosaccharides, with a focus on developing methodologies that reduce the number of protecting-group manipulations, control stereochemistry of the glycosidic bonds, and eliminate labor-intensive purifications.

Contemporary advances in synthesis emphasize the efficiency of preparing complex oligosaccharides by using automated synthesis,[4] one-pot procedures,[5] and chemoenzymatic processes.[6] One of the most exciting developments is exemplified in the multi-gram production of iGb3, which was obtained as the free trisaccharide by using E. coli.[7] This approach holds enormous potential and provides impetus for the concomitant development of generalized methods for conjugating free sugars. Indeed, Castillon et al. recently showed that commercially available iGb3 could be per-O-acetylated (per-O-Ac) and converted into a glycosyl iodide, which underwent glycosylation with the tin acetal of ceramide (Scheme 1).[8] This finding encouraged us to explore a similar strategy to introduce functionalized linkers that could be useful tools for multivalent display of carbohydrate head groups.[9] We imagined a conjugation methodology that would begin with readily available per-O-acetylated oligosaccharides derived from either synthetic or natural sources. Activation of the anomeric acetate, and subsequent trapping with a suitable acceptor, would afford the corresponding glycoconjugate after removal of the acetate protecting groups. In this manner, various sugars could be functionalized for the preparation of sugar arrays for high-throughput screening[10] and applications in chemotherapeutics development.[11] We were especially interested in controlling the stereochemistry at the anomeric position because the chiral center may affect bioassay results.[12]

Scheme 1.

Scheme 1

Castillon's iGb3 synthesis.

Based upon earlier results from our lab, our efforts focused on the idea of using trimethylene oxide (TMO) as an acceptor. We had reported the unique reactivity of armed ether-protect­ed glycosyl iodides with oxa- and thiocycloalkane acceptors (Scheme 2)[13] to yield iodoalkyl conjugates with high stereo-control. The SN2-like displacement provided a convenient way to functionalize fully protected sugars in two consecutive steps.

Scheme 2.

Scheme 2

TMO addition to ether-protected glycosyl iodides affords β-glycosides (Bn=benzyl).

Preparing benzyl-protected monosaccharides with an anomeric acetate is relatively straightforward, but requires several steps and is not well suited for oligosaccharides. Per-O-silylation of oligosaccharides can be achieved in a single step, but conversion of the anomeric silyl ether into the corresponding glycosyl iodide is often complicated by competing cleavage of internal glycosidic linkages, resulting in a complex mixture of degradation products. In contrast, acetylation is a commonly used protecting group for carbohydrate isolation and purification.[14] The electron-withdrawing nature of acetyl protecting groups stabilizes glycosidic linkages and provides well-resolved proton NMR spectra, facilitating quality control and compound characterization. However, a major challenge of utilizing ester-protected glycosyl iodides is their lack of reactivity. Per-O-acetylated glycosyl iodides have been shown to survive aqueous extractions, column chromatography, and are even so stable that X-ray crystal structures have been obtained.[15] The “disarmed”[16] nature of ester-protected glycosyl iodides necessitates using a promoter (Lewis acids or metals) or heat to afford reasonable yields of the glycosylation products. In addition, C-2 ester-protected glycosyl donors often form orthoesters as a side reaction.[17] For example, in the case of iGb3 noted above, stannyl alkoxides were needed for efficient addition and a Lewis acid was required to avoid orthoester formation.[8, 18] Other groups have successfully prepared β-linked glycosides from ester-protected glycosyl iodides by using various activating reagents, including NIS/I2/TMSOTf (NIS=N-iodosuccinimide, Tf=triflate),[17] I2/DDQ (DDQ=2,3-dichloro-5,6-dicyano-1,4-benzoquinone),[19] and NBS/Zn (NBS=N-bromosuccinimide) salts.[20] These methods all have their merits, but the substrates were limited to monosaccharides and, in most cases, long reaction times were required. These findings suggested to us that a rapid and generalized conjugation methodology for ester-protected glycosyl iodides is still needed.

Herein, we report an anomeric-functionalization methodology that combines per-O-Ac glycosyl iodide formation and I2-promoted TMO addition under microwave irradiation (Figure 1). The formed β-glycosides were functionalized with an iodopropyl linker at the anomeric position, serving as a useful chemical handle for further manipulations. With the functionalized glycosides in hand, multivalent glycoconjugates and glycopeptides were constructed to demonstrate the utility of this methodology.

Figure 1.

Figure 1

A universal functionalization method for per-O-Ac oligosaccharides.

Results and Discussion

Previous reports from our lab showed per-O-TMS glycosyl iodides to be highly reactive donors, which when coupled with various acceptors form glycoconjugates with exquisite stereo-control.[21] Although the methodology worked well with monosaccharide-derived iodides, TMSI-promoted glycosylation of oligosaccharides was complicated and consistently led to a complex reaction mixture in a short period of time (<30 min). Crude MS analysis revealed bond cleavage, trans-silylation, and desilylation products.[21a, 22] Mindful of the fact that glycosyl iodide reactivity is highly attenuated by acetate protecting groups, we prepared C-6,6′ acetate analogues 1 and 2 by using regioselective silyl exchange technology (ReSET) of per-O-silyl lactose.[22,23] We hoped that incorporation of the acetates would protect the inter-glycosidic linkage from cleavage and that the presence of the remaining silyl ethers would sufficiently activate the iodide. Remarkably, when compound 1 or 2 was treated with TMSI, the corresponding iodide (3) was obtained without internal-bond cleavage or silyl migration.[22] Trimethylene oxide (TMO) was then introduced to the iodide and the reaction mixture was kept in the dark for 36 h. After acidic methanolysis to remove the silyl protecting groups and reacetylation for isolation and characterization purposes, the β-TMO adduct (4) was obtained in 56% yield over four steps (Scheme 3). The glycosylation required no promoter or heat, indicating that iodide 3 is a highly reactive donor.

Scheme 3.

Scheme 3

6,6′-Di-O-acetylated lactosyl iodide reacts with TMO.

Encouraged by these results, we turned our attention to per-O-acetylated oligosaccharides. Investigations began with the study of β-lactose octaacetate (), which was treated with TMSI and monitored by NMR spectroscopy to observe iodide formation. Unlike benzylated or silylated analogues, which formed the corresponding α-iodides within minutes, first formed and then gradually anomerized to the α-iodide () over six to eight hours.[24] When treating the β-iodide () with 1.5 equivalents of TMO at room temperature, the corresponding orthoester (7) was obtained in 88% yield after eight hours. In contrast, the α-iodide () was unreactive at room temperature; even after five days at 40°C only a low yield of the desired glycoconjugate (4) was produced, along with unreacted (Scheme 4). These results led us to conclude that a suitable promoter that avoids orthoester formation is necessary to optimize the production of 4.

Scheme 4.

Scheme 4

Results of TMO-addition reaction to “disarmed” per-O-Ac lactosyl iodide.

Several groups have observed orthoester formation during glycosylation studies.[15b, 19b, 20a, 25] Common methods to circumvent this side reaction include introducing a Lewis acid or applying heat to the reaction.[20b, 26] Initially, we followed the method reported by Stachulsky et al.,[15b] utilizing NIS and triflic acid, but only 20–30% yield of 4 was obtained. We then explored I2-promoted glycosidation[19] in combination with microwave irradiation to heat the reaction more efficiently.[27] Having observed significant reactivity differences between the lactosyl iodide anomers, our study evaluated I2 activation of and independently (Scheme 5). In each case, commercially available per-O-acetylated lactose was treated with TMSI to generate the lactosyl iodide, which was monitored by real-time NMR spectroscopy[24] or TLC analysis; the two lactosyl iodide anomers are distinguishable by TLC analysis (see the Supporting Information, Figure S1). Once each iodide was in hand, TMO and I2 were added to the flask and the reaction was subjected to microwave irradiation (Scheme 5). We hypothesized that the anomers might have different reactivity and glycosylation profiles, but the yields were similar, being only slightly higher for the β-anomer. Reactions of and with TMO gave target molecule 4 in 51–57% yield, di-TMO adduct 8 in 12–15% yield, and per-O-Ac lactose 5 in 9–13% yield, suggesting that both anomers proceed through a common reaction intermediate (Scheme 5).

Scheme 5.

Scheme 5

I2-promoted TMO addition under microwave irradiation.

Based upon studies by Field et al.,[19b] Murakami et al.,[20a] and Demchenko et al.,[28] a proposed mechanism of I2-promoted TMO addition is shown in Figure 2. Both α-iodide and β-iodide can be activated by I2, forming a better leaving group at the anomeric position. The C-2 acetate is positioned to displace the activated β-triiodide intramolecularly, forming the α-face-blocking oxonium ion. Direct attack by TMO at the anomeric position affords the β-glycoside after iodide opening of the activated oxetane. The small amount of α-TMO-adduct formation may result from TMO attack on the α-face, but this occurs to a lesser extent because neighboring-group participation predominates.

Figure 2.

Figure 2

Proposed mechanism for I2-promoted TMO addition.

The di-TMO adduct (8) had a similar Rf value as the target mono-TMO adduct (4), making isolation difficult and lowering the yield. Different reaction temperatures (0–70°C) were screened, but compound 8 was observed in all instances. We reasoned that the side product could be forming by means of a radical side reaction and decided to introduce butylated hydroxytoluene (BHT), a common radical scavenger,[29] to suppress possible radical formation (Table 1). When using CH2Cl2 as solvent, compound 4 was obtained in 61% yield, but trace amounts of 8 were still observed (Table 1, entry 1). When changing the solvent to CHCl3, compound 4 was isolated in 51% yield and compound 8 did not form, as evidenced by TLC and crude MS analysis. However, the reaction in CHCl3 also gave the α-TMO adduct in trace amounts. This adduct usually co-eluted with per-O-Ac lactose (Table 1, entry 2). Using benzene as the solvent led to target molecule 4 in 54% yield, but it took longer to generate the iodide and the amount of α-TMO-adduct side product slightly increased (Table 1, entry 3).

Table 1.

Optimization of TMO addition by introducing BHT and different solvents.

graphic file with name nihms703066u1.jpg

Entry Solvent Iodide formation t [min] Isolated yield of 4 [%] Byproducts (≈20–30%)
1 CH2Cl2 40 61 di-TMO adduct (8), per-O-Ac lactose (5)
2 CHCl3 50 51 alpha anomer, per-O-Ac lactose (5)
3 PhH 90 54 alpha anomer, per-O-Ac lactose (5)

Taking purification and reaction time into consideration, we decided to use 1.2 equivalents of TMSI in CHCl3 for iodide formation, 1.5 equivalents of TMO, 1.0 equivalent of I2, and 50 mol% of BHT, under microwave irradiation at 70°C for 20 min (Table 1 entry 2), as the standard conditions to explore the methodology with different per-O-Ac sugars (Table 2). Commercially available per-O-Ac monosaccharides (, 10β, 10α, and 11α) were first subjected to the glycosyl iodide/TMO addition reaction. Iodide formation time was established at the time the per-O-acetylated starting material had been completely consumed. In general, the β-acetates ( and 10β) reacted faster than the α-acetates (10α and 11α) in TMSI-promoted iodide formation,[30] and led to slightly better yields of the corresponding TMO adduct (Table 2, entries 1 and 2 versus Table 2 entries 3 and 4). β-Glucose pentaacetate () and β-galactose pentaacetate (10β) reacted to form the corresponding iodides in less than one hour, and afforded the corresponding TMO adducts (13 and 14) in 84 and 87% yields, respectively (Table 1, entries 1 and 2). Galactose was slightly more reactive than glucose in both iodide formation and TMO glycosidation. In contrast, 10α required a longer reaction time (2.5 h) to be completely consumed in the iodide formation step. After I2-promoted TMO glycosylation, the reaction afforded 14 in a slightly lower yield of 79% (Table 1, entry 3). We attributed the increased reactivity of the β-anomers to neighboring-group participation. Nevertheless, using either α- or β-acetates gave rise to the same β-TMO adduct (14), providing further evidence of common reaction intermediates. The methodology was extended to include α-mannose pentaacetate (11α). Iodide formation of 11α required 4.5 h to complete, and the corresponding α-TMO adduct (15) was obtained in 71% yield (Table 2, entry 4).

Table 2.

TMO-addition results for per-O-Ac sugars.

graphic file with name nihms703066u2.jpg

Entry Starting material Iodide formation Product (isolated yield [%])
1 graphic file with name nihms703066t1.jpg 50 min graphic file with name nihms703066t2.jpg 84
2 graphic file with name nihms703066t3.jpg 40 min graphic file with name nihms703066t4.jpg 87
3 graphic file with name nihms703066t5.jpg 2.5 h 14 79
4 graphic file with name nihms703066t6.jpg 4.5 h graphic file with name nihms703066t7.jpg 71
5 graphic file with name nihms703066t8.jpg 50 min graphic file with name nihms703066t9.jpg 51
6 graphic file with name nihms703066t10.jpg 1 h graphic file with name nihms703066t11.jpg 72

Not only could we apply the methodology to the monosaccharides and per-O-Ac lactose (), but also the per-O-Ac globotriaose (12), which was obtained from ReSET modules.[22] Compound 12 was a mixture of anomeric acetates in a ratio of α/β=1:5. The iodide formation was completed within one hour and led to the corresponding β-TMO adduct (16) in 72% yield. It is worth noting that the per-O-Ac globotriaose (α/β=1:1) starting material could be isolated in the same reaction. Based on the recovery of starting material, the yield of the desired β-TMO adduct (16) was 81% (Table 2, entry 6). These encouraging results illustrate the broad potential for modification of other per-O-acetylated oligosaccharides, whether obtained commercially or isolated from a natural source.

With the iodopropyl-containing oligosaccharides in hand, we started exploring further applications of the functionalized oligosaccharides. Both compounds 4 and 16 were transformed to azide compounds 17 and 19 in over 90% yields. After global deacetylation by using NaOMe/MeOH, compounds 18 and 20 were obtained in quantitative yields and contained useful “chemical handles” for further modifications (Scheme 6).

Scheme 6.

Scheme 6

Synthesis of functionalized lactose 18 and globotriaose 20.

Cu-catalyzed azide–alkyne cycloaddition (CuAAC)[31] allowed us to construct multivalent glycoconjugates. Tetraalkyne 21[32] was chosen as the core structure for the display. When azido lactose 17 was stirred with 21 in DMF/H2O with CuSO4·5H2O, sodium ascorbate and tris-(benzyltriazolylmethyl)amine (TBTA),[33] the protected lactose tetramer was obtained after 20 h. The protected lactose tetramer was treated with NaOMe/MeOH for one hour to afford the fully deprotected lactose tetramer (22) in 78% yield over two steps. When using azido triglobotriaose 19 as the reagent, globotriaose tetramer 23 was obtained in 60% yield after the two-step CuAAC–deprotection procedure (Scheme 7). Both compounds 22 and 23 were water soluble, and served as important substrates for ongoing biological studies in our laboratory.

Scheme 7.

Scheme 7

Construction of lactose and globotriaose tetramers 22 and 23.

Previously, our lab demonstrated using copper-catalyzed azide–alkyne cycloaddition to construct a synthetic trivalent mimotope of HIV gp120 conjugated to pan allelic HLA DR binding epitope (PADRE), which displayed enhanced binding affinity to HIV-1-neutralizing monoclonal antibody, MAb b12.[32a, 34] PADRE,[35] a known artificial T-helper (TH) epitope containing thirteen amino acids, has not only been used in HIV research, but also in cancer-vaccine development as an immunogenic carrier to stimulate the immune response. The combination of tumor-associated carbohydrate antigens (TACAs) and PADRE has been demonstrated by Dumy et al. as a new family of immunostimulants.[36] This new class of multivalent glycoconjugates could also provide promising antitumor-vaccine candidates in the future.[11c, 37] Applying the TMO-addition concept and click chemistry, trimeric globotriaose–PADRE conjugate 25 was constructed as a potential cancer-vaccine candidate (Scheme 8). Following the published protocol,[32, 38] compounds 20 and 24[32] were reacted with sodium ascorbate, aminoguanidine, CuSO4·5H2O, and tris(3-hydroxypropyltriazolylmethyl)amine ligand (THPTA) in PBS buffer pH 7.4 containing 5% DMSO, under O2-free conditions overnight. After desalting, purification, and lyophilization procedures, the trimeric globotriaose–PADRE conjugate (25) was obtained as a fluffy white solid in 75% yield, and was analyzed by MALDI-TOF MS and analytical HPLC (see the Supporting Information, Figure S2 and S3). The biological activity of this construct is currently under investigation.

Scheme 8.

Scheme 8

Synthesis of globotriaose–PADRE construct as a cancer-vaccine candidate.

Conclusion

A rapid, step-economical, one-pot methodology for the functionalization of per-O-Ac oligosaccharides has been developed. The methodology integrates in situ iodide formation by using TMSI and I2-promoted TMO addition to form iodopropyl-linked per-O-Ac β-glycosides. A proposed mechanism for the I2-promoted TMO addition by using per-O-Ac iodide highlights neighboring-group participation at the C-2 position. The mechanism explains the observed stereochemistry, and microwave irradiation hastens the process allowing efficient conjugation within 20 min, compared to hours or days in previously reported methods.

The iodopropyl linker serves as a useful chemical handle for further manipulation. One application is to transform the terminal iodide into the corresponding azide for click chemistry. With the proper alkyne cores, multivalent glycoconjugates were readily prepared in respectable yields. These multivalent glycoconjugates (23 and 25) contain tumor-associated carbohydrate antigens (TACAs) and immuno-stimulating peptides (PADRE), presenting potential applications as cancer-vaccine or adjuvant candidates.

Experimental Section

3-Iodopropyl (2,3,4,6-tetra-O-acetyl-β-O-d-galactopyranosyl)-(1-4)-O-2,3,6-tri-O-acetyl-β-d-glucopyranoside (4)

Method A

In an oven-dried NMR tube, compound 2 (66 mg, 0.08 mmol) was dissolved in dry [D6]benzene (0.8 mL). After TMSI (13 μL, 0.10 mmol) was introduced to the reaction vessel, the reaction was kept at 10°C and gradually warmed to room temperature over 4–5 h. The reaction was monitored by proton NMR spectroscopy until the corresponding iodide (6) formed in situ. Next, trimethylene oxide (TMO, 16 μL, 0.24 mmol) was added to the reaction vessel and the reaction was allowed to react in the dark for 36 h. The reaction mixture was then azeotroped with dry benzene (5 mL×3) to remove excess reagent and solvent. The resulting residue was dissolved in MeOH (5 mL) and stirred with the Dowex acidic resin (pH ≈3) at room temperature. After 2 h, the resin was filtered and the solvent was evaporated under reduced pressure to afford a viscous orange oil. The resulting oil was then dissolved in CH2Cl2 (1 mL) under Ar. Ac2O (1.0 mL), NEt3 (1.5 mL), and catalytic 4-dimethylaminopyridine (DMAP, ≈2 mg) were then added to the solution, and the reaction mixture was stirred at room temperature overnight. Next, the reaction mixture was concentrated under reduced pressure, and the resulting oil was purified by using flash column chromatography (ethyl acetate/n-hexane=50:50) to afford compound 4 (36 mg, 56% yield) as a white foam (Scheme 2).

Method B

To a 10 mL microwave reaction vessel, compound (150 mg, 0.22 mmol) was dissolved in anhydrous CH2Cl2 (2 mL) and TMSI (39 μL, 0.27 mmol) was added under Ar. After 50 min, TLC analysis revealed the complete consumption of starting material. TMO (22 μL, 0.33 mmol) and I2 (56 mg, 0.22 mmol) were then added to the reaction mixture. The reaction vessel was sealed and subjected to microwave irradiation for 20 min (standard mode, 70°C, ≈40 psi, ≈70 W). The reaction mixture was then diluted with ethyl acetate (30 mL), and washed with saturated Na2S2O3 (aq.) (20 mL) and brine (20 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure, and purified by gradient flash column chromatography (ethyl acetate/n-hexane = 40:60 to 50:50) to obtain compound 4 (99 mg, 57% yield), compound 8 (25 mg, 13% yield), and 5 (13 mg, 9% yield) as white foams (Scheme 4). Data for compound 4: Rf=0.43 (ethyl acetate/n-hexane=1:1). [α]D20=+1.1(c0.47,CHCl3); 1H NMR (600 MHz, CDCl3): δ = 5.35 (d, J = 3.5 Hz, 1H, H-4′), 5.20 (appt. t, J = 9.5 Hz, 1H, H-3), 5.11 (dd, J=10.4, 7.9 Hz, 1H, H-2′), 4.95 (dd, J=10.4, 3.5 Hz, 1H, H-3′), 4.88 (dd, J = 9.5, 8.0 Hz, 1H, H-2), 4.15–4.47 (m, 3H, H-1, H-1′, H-6a), 4.19–4.05 (m, 3H, H-6ab, H-6′b), 3.92–3.86 (m, 2H, OCH, H-5), 3.79 (appt. t, J = 9.5 Hz, 1H, H-4), 3.62–3.56 (m, 2H, CH2I), 2.15 (s, 3H), 2.13 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 2.05 (s, 6H), 1.97 ppm (s, 3H); 13C NMR (150 MHz, CDCl3) δ = 170.4, 170.3, 170.2, 170.1, 169.8, 169.7, 169.1, 101.1, 100.7, 76.3, 72.7, 72.6, 71.6, 71.0, 70.7, 69.2, 69.1, 66.6, 61.9, 60.8, 32.8, 20.9, 20.85, 20.82, 20.67, 20.66, 20.65, 20.5, 3.0 ppm; HRMS (ESI-ion trap): m/z calcd for C29H41IO18 + NH4+: 822.1676 [M + NH4+]; found: 822.1692.

α-(2,3,4,6-Tetra-O-acetyl-β-O-d-galactopyranosyl)-(1-4)-O-2,3,6-tri-O-acetyl-β-d-glucopyranosyl iodide (6α)

In an oven-dried NMR tube, compound (100 mg, 0.15 mmol) was dissolved in dry CDCl3 (0.5 mL). After TMSI (23 μL, 0.16 mmol) was introduced at room temperature, the reaction was monitored by proton NMR spectroscopy until the corresponding α-iodide () formed in situ (≈6 h). Rf=0.15 (ethyl acetate/n-hexane = 2:3); In situ 1H NMR (600 MHz, CDCl3): δ = 6.92 (d, J = 4.3 Hz, 1H, H-1), 5.47 (appt. t, J = 9.5 Hz, 1H, H-3), 5.36 (d, J = 3.4 Hz, 1H, H-4′), 5.13 (dd, J=10.4, 7.9 Hz, 1H, H-2′), 4.97 (dd, J=10.4, 3.5 Hz, 1H, H-3′), 4.57–4.44 (m, 2H, H-1′, H-6a), 4.24–4.04 (m, 5H, H-2, H-5′, H-6b, H-6′a), 3.97 (dd, J = 10.1, 2.2 Hz, 1H, H-5), 3.90–3.87 (m, 2H, H-4, H-6′b), 2.16 (s, 3H), 2.13 (s, 3H), 2.09 (s, 3H), 2.07–2.06 (m, 9H), 1.97 ppm (s, 3H); In situ 13C NMR (150 MHz, CDCl3): δ = 170.3, 170.2, 170.1, 169.8, 169.2, 168.9, 164.8, 100.8, 75.7, 74.7, 72.6, 71.1, 71.0, 70.8, 70.6, 69.1, 66.6, 60.9, 60.8, 29.7, 29.3, 20.8, 20.79, 20.68, 20.67, 20.6, 20.5 ppm; HRMS (ESI-ion trap): m/z calcd for C26H35IO17 + NH4+: 764.1257 [M + NH4+]; found: 764.1279.

β-(2,3,4,6-Tetra-O-acetyl-β-O-d-galactopyranosyl)-(1-4)-O-2,3,6-tri-O-acetyl-β-d-glucopyranosyl iodide (6β)

In an oven-dried NMR tube, compound (100 mg, 0.15 mmol) was dissolved in dry CDCl3 (0.5 mL). After TMSI (23 μL, 0.16 mmol) was introduced at room temperature, the reaction was monitored by proton NMR spectroscopy until the corresponding β-iodide () formed in situ (≈40 min). Rf=0.50 (ethyl acetate/n-hexane = 2:3); In situ 1H NMR (400 MHz, CDCl3): δ = 5.73 (d, J = 8.8 Hz, 1H, H-1), 5.29 (d, J = 2.9 Hz, 1H, H-4′), 5.18 (appt t, J = 8.8 Hz, 1H, H-2), 5.10–5.01 (m, 2H, H-3, H-2′), 4.91 (dd, J=10.4, 3.3 Hz, 1H, H-3′), 4.52–4.34 (m, 2H, H-1′, H-6a), 4.13–3.99 (m, 3H, H-6b, H-6′ab), 3.93 (appt. t, J = 9.5 Hz, 1H, H-4), 3.85 (appt. t, J = 6.7 Hz, 1H, H-5′), 3.64 (dd, J= 10.0, 3.3 Hz, 1H, H-5), 2.09 (s, 3H), 2.08 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 2.00 (s, 3H), 1.99 (s, 3H), 1.91 ppm (s, 3H); In situ 13C NMR (100 MHz, CDCl3): δ = 170.2, 170.1, 170.0, 169.9, 168.5, 169.0, 168.9, 100.9, 78.1, 75.3, 75.2, 72.6, 70.8, 70.5, 68.9, 66.5, 61.7, 60.7, 56.6, 20.7, 20.65, 20.61, 20.51, 20.50, 20.46, 20.3 ppm; HRMS (ESI-ion trap): m/z calcd for C26H35IO17 + NH4+: 764.1257 [M + NH4+]; found: 764.1264.

Per-O-Ac lactose TMO orthoester (7)

In an oven-dried NMR tube, compound (50 mg, 0.07 mmol) was dissolved in dry CHCl3 (0.5 mL). After TMSI (11 μL, 0.08 mmol) was introduced, the reaction was monitored by proton NMR spectroscopy until the starting material was completely consumed. Once the β-iodide () formed, TMO (16 μL, 0.24 mmol) was added to the reaction vessel and the reaction was allowed to react in the dark for 8 h. The reaction mixture was then azeotroped with dry benzene to remove the excess solvent and reagents. The resulting residue was purified by using flash column chromatography (ethyl acetate/n-hexane = 60:40) to afford compound 7 (52 mg, 88% yield) as a white foam. Rf=0.46 (ethyl acetate/n-hexane = 3:2); 1H NMR (600 MHz, CDCl3): δ = 5.67 (d, J = 5.1 Hz, 1H, H-1), 5.55–5.53 (m, 1H, H-3), 5.38 (d, J = 2.8 Hz, 1H, H-4′), 5.18 (dd, J = 10.4, 8.1 Hz, 1H, H-2′), 5.00 (dd, J = 10.4, 3.5 Hz, 1H, H-3′), 4.61 (d, J = 8.0 Hz, 1H, H-1′), 4.32 (dd, J = 4.6, 2.2 Hz, 1H, H-2), 4.25 (dd, J = 12.0, 2.3 Hz, 1H, H-6a), 4.15–4.08 (m, 3H, H-6b, H-6′ab), 3.94 (appt. t, J = 6.8 Hz, 1H, H-5′), 3.86–3.82 (m, 1H, H-5), 3.64 (d, J = 9.6 Hz, 1H, H-4), 3.60–3.52 (m, 2H, OCH2), 3.24 (appt. t, J = 6.6 Hz, 2H, CH2I), 2.17 (s, 3H), 2.12 (s, 3H), 2.11 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H), 1.97 (s, 3H), 1.73 ppm (s, 3H); 13C NMR (150 MHz, CDCl3): δ = 170.7, 170.3, 170.2, 170.1, 169.4, 169.1, 121.4, 102.4, 96.8, 72.8, 70.9,70.8, 69.9, 68.8, 66.9, 66.8, 63.4, 62.9, 60.9, 32.9, 20.9, 20.8, 20.7,20.68, 20.64, 20.5, 20.3, 3.0 ppm; HRMS (ESI-ion trap): m/z calcd for C29H41IO18 + NH4+: 822.1676 [M + NH4+]; found: 822.1696.

3-(3-Iodopropoxy)propyl (2,3,4,6-tetra-O-acetyl-β-O-d-galactopyranosyl)-(1-4)-O-2,3,6-tri-O-acetyl-β-d-glucopyranoside (8)

Compound 8 (25 mg, 13%) was obtained as a white foam (see compound 4, method B for reaction and purification conditions). Rf = 0.41 (ethyl acetate/n-hexane =1:1); 1H NMR (600 MHz, CDCl3): δ = 5.35 (d, J = 2.5 Hz, 1H, H-4′), 5.22–5.17 (m, 1H, H-3), 5.11 (dd, J=10.3, 8.0 Hz, 1H, H-2′), 4.95 (dd, J=10.3, 3.4 Hz, 1H, H-3′), 4.91–4.86 (m, 1H, H-2), 4.48 (dd, J=14.9, 6.7 Hz, 3H, H-1, H-1′, H-6a), 4.20–4.04 (m, 3H, H-6b, H-6′ab), 3.95–3.85 (m, 2H, H-5′, OCH), 3.79 (appt. t, J = 9.4 Hz, 1H, H-4), 3.68–3.54 (m, 2 H, H-5, OCH), 3.49–3.44 (m, 4H, OCH2×2), 3.26 (appt. t, J = 6.7 Hz, 2H, CH2I), 2.15 (s, 3H), 2.12 (s, 3H), 2.06 (s, 3H), 2.04 (s, 6H), 1.96 (s, 3H), 1.88–1.78 ppm (m, 2H); 13C NMR (150 MHz, CDCl3): δ = 170.4, 170.3, 170.1, 170.0, 169.8, 169.6, 169.1, 101.1, 100.7, 76.3, 72.8, 72.6, 71.7, 70.9, 70.7, 70.0, 69.0, 67.2, 67.0, 66.6, 62.0, 60.8, 33.3, 29.8, 20.9, 20.8, 20.7, 20.64, 20.63, 20.5, 3.5 ppm; HRMS (ESI-ion trap): m/z calcd for C32H47IO19 + NH4+: 880.6519 [M + NH4+]; found: 880.6500.

General procedure for optimized TMO-addition reaction (Table 2)

The per-O-Ac sugar (β-d-glucose pentaacetate (), β-d-galactose pentaacetate (10β), α-d-galactose pentaacetate (10α), α-d-mannose pentaacetate (11α), β-d-lactose octaacetate (), and per-O-Ac globotriaose(12)) was placed in 10 mL microwave reaction vessels with a stir bar in a vacuum oven at 80°C overnight before the reaction was carried out. After the reaction vessel was cooled to room temperature in an Ar-filled desiccator, the reaction vessel was sealed with a Teflon cap. Anhydrous CHCl3 (2 mL) was added to the reaction vessel to dissolve the per-O-Ac sugar (0.25 mmol, 1.0 equiv), followed by TMSI (0.3 mmol, 1.2 equiv) at room temperature. After the appropriate reaction time interval (Table 2), TLC analysis revealed the complete consumption of starting material. Next, butylated hydroxytoluene (BHT, 0.13 mmol, 0.5 equiv), TMO (0.38 mmol, 1.5 equiv), and I2 (0.25 mmol, 1.0 equiv) were added to the reaction mixture. The reaction vessel was then subjected to microwave irradiation for 20 min (standard mode, 70°C, ≈40 psi, ≈70 W). The reaction mixture was diluted with ethyl acetate (30 mL), and washed with saturated Na2S2O3 (aq.) (20 mL) and brine (20 mL). The organic layer was dried over Na2SO4, concentrated under reduced pressure, and the resulting residue was purified by using gradient flash column chromatography (ethyl acetate/n-hexane) to obtain the corresponding per-O-Ac-TMO adduct (4, 13, 14, 15, and 16) as a white foam.

3-Iodopropyl 2,3,4,6-tetra-O-acetyl-β-d-glucopyranoside (13)

Following the general procedure for optimized TMO addition, β-d-glucose pentaacetate () (100 mg, 0.26 mmol) was dissolved in dry CHCl3 (2 mL) and treated with TMSI (44 μL, 0.31 mmol). After the starting material was completely consumed, BHT (28 mg, 0.13 mmol), TMO (26 μL, 0.29 mmol), and I2 (66 mg, 0.26 mmol) were added to the reaction mixture, followed by microwave irradiation for 20 min (standard mode, 70°C, ≈40 psi, ≈70 W). After workup, the resulting residue was purified by gradient flash column chromatography (ethyl acetate/n-hexane =40:60 to 50:50) to obtain 13 (113 mg, 84% yield) as a white foam (Table 2, entry 1). Rf = 0.45 (ethyl acetate/n-hexane = 2:3). [α]D25=+2.9(c0.84,CHCl3); 1H NMR (800 MHz, CDCl3): δ = 5.21 (appt. t, J = 9.6 Hz, 1H, H-3), 5.08 (t, J = 9.7 Hz, 1H, H-4), 4.98 (dd, J = 9.6, 8.0 Hz, 1H, H-2), 4.52 (d, J = 8.0 Hz, 1H, H-1), 4.27 (dd, J= 12.3, 4.8 Hz, 1H, H-6a), 4.15 (dd, J= 12.3, 2.3 Hz, 1H, H-6b), 3.94 (dt, J = 9.9, 5.0 Hz, 1H, OCH), 3.71 (ddd, J = 9.9, 4.7, 2.4 Hz, 1H, H-5), 3.62–3.57 (m, 1H, OCH), 3.28–3.19 (m, 2H, RCH2I), 2.09 (s, 3H), 2.07 (s, 3H), 2.02 (s, 3H), 2.00 (s, 3H), 2.07–1.95 ppm (m, 2H, CH2); 13C NMR (200 MHz, CDCl3): δ = 170.7, 170.3, 169.4, 169.3, 101.0, 72.7, 71.8, 71.2, 69.2, 68.4, 61.9, 32.7, 20.8, 20.7, 20.6, 20.5, 3.09 ppm; HRMS (ESI-ion trap): m/z calcd for C17H25IO10 + NH4+: 534.0831 [M + NH4+]; found: 534.0831.

3-Iodopropyl 2,3,4,6-tetra-O-acetyl-β-d-galactopyranoside (14)

Following the general procedure for optimized TMO addition, β-d-galactose pentaacetate (10β) (100 mg, 0.26 mmol) was dissolved in dry CHCl3 (2 mL) and was treated with TMSI (44 μL, 0.31 mmol). After the starting material was completely consumed, BHT (28 mg, 0.13 mmol), TMO (26 μL, 0.29 mmol), and I2 (66 mg, 0.26 mmol) were added to the reaction mixture, followed by microwave irradiation for 20 min (standard mode, 70°C, ≈40 psi, ≈70 W). After workup, the resulting residue was purified by gradient flash column chromatography (ethyl acetate/n-hexane=40:60 to 50:50) to obtain 14 (117 mg, 87% yield) as a white foam (Table 2, entry 2). Rf = 0.38 (ethyl acetate/n-hexane = 2:3). [α]D25=+9.1(c1.19,CHCl3); 1H NMR (800 MHz, CDCl3): δ = 5.40 (d, J = 3.5 Hz, 1H, H-4), 5.19 (dd, J= 10.5, 8.0 Hz, 1H, H-2), 5.03 (dd, J= 10.5, 3.5 Hz, 1H, H-3), 4.49 (d, J = 8.0 Hz, 1H, H-1), 4.19 (dd, J=11.3, 6.8 Hz, 1H, H-6a), 4.13 (dt, J = 6.8, 5.4 Hz, 1H, H-6b), 3.96 (dt, J = 9.8, 4.9 Hz, 1H, OCH), 3.92 (appt. t, J = 6.8 Hz, 1H, H-5), 3.63–3.57 (m, 1H, OCH), 3.29–3.21 (m, 2H, RCH2I), 2.15 (s, 3H), 2.10 (s, 3H), 2.06 (d, 3H), 1.99 (s, 3H), 2.11–1.95 ppm (m, 2H, CH2); 13C NMR (200 MHz, CDCl3): δ = 170.4, 170.3, 170.2, 169.5, 101.5, 70.8, 70.7, 69.2, 68.8, 67.0, 61.3, 32.7, 20.9, 20.7, 20.66, 20.6, 3.2 ppm; HRMS (ESI-ion trap): m/z calcd for C17H25IO10 + NH4+: 534.0831 [M + NH4+]; found: 534.0830.

3-Iodopropyl 2,3,4,6-tetra-O-acetyl-α-d-mannopyranoside (15)

Following the general procedure for optimized TMO addition, α-D-mannose pentaacetate (11 α) (100 mg, 0.26 mmol) was dissolved in dry CHCl3 (2 mL) and was treated with TMSI (44 μL, 0.31 mmol). After the starting material was completely consumed, BHT (28 mg, 0.13 mmol), TMO (26 μL, 0.29 mmol), and I2 (66 mg, 0.26 mmol) were added to the reaction mixture, followed by microwave irradiation for 20 min (standard mode, 70°C, ≈40 psi, ≈70 W). After workup, the resulting residue was purified by gradient flash column chromatography (ethyl acetate/n-hexane=40:60 to 50:50) to obtain 15 (113 mg, 84% yield) as a white foam (Table 2, entry 4). Rf = 0.55 (ethyl acetate/n-hexane = 2:3); [α]D25=+43.3(c0.30,CHCl3); 1H NMR (800 MHz, CDCl3): δ = 5.31–5.27 (m, 2H, H-2, H-4), 5.24 (dd, J = 3.0, 1.6 Hz, 1H, H-2), 4.83 (d, J= 1.6 Hz, 1H, H-1), 4.29 (dt, J=13.8, 6.9 Hz, 1H, H-6a), 4.16–4.13 (m, 1H, H-6b), 4.04–4.00 (m, 1H, H-5), 3.84–3.81 (m, 1H, OCH), 3.55–3.50 (m, 1H, OCH), 3.33–3.25 (m, 2H, CH2I), 2.16 (s, 3H), 2.13–2.04 (m, 2H, CH2) 2.11 (s, 3H), 2.05 (s, 3H), 2.00 ppm (s, 3H); 13C NMR (200 MHz, CDCl3): δ = 170.7, 170.1, 169.9, 169.7, 97.7, 69.5, 69.1, 68.7, 67.3, 66.0, 62.5, 32.6, 20.9, 20.8, 20.7, 20.6, 2.8 ppm; HRMS (ESI-ion trap): m/z calcd for C17H25IO10 + NH4+: 534.0831 [M + NH4+]; found: 534.0836.

3-Iodopropyl (2,3,4,6-Tetra-O-acetyl-α-d-galactopyranosyl)-(1-4)-O-(2,3,6-tri-O-acetyl-β-O-d-galactopyranosyl)-(1-4)-O-2,3,6-tri-O-acetyl-β-d-glucopyranoside (16)

Following the general procedure for optimized TMO addition, per-O-Ac globotriaose (12) (210 mg, 0.22 mmol) was dissolved in dry CHCl3 (2 mL) and treated with TMSI (48 μL, 0.33 mmol). After the starting material was completely consumed, BHT (22 mg, 0.11 mmol), TMO (22 μL, 0.29 mmol), and I2 (56 mg, 0.26 mmol) were added to the reaction mixture, followed by microwave irradiation for 20 min (standard mode, 70°C, ≈40 psi, ≈70 W). After workup, the resulting residue was purified by gradient flash column chromatography (ethyl acetate/n-hexane=50:50 to 60:40) to obtain 16 (170 mg, 72% yield) as a white foam (Table 2, entry 6). Rf=0.38 (ethyl acetate/n-hexane = 2:1); 1H NMR (800 MHz, CDCl3): δ = 5.59 (d, J = 2.6 Hz, 1H, H-4′), 5.39 (dd, J=11.0, 3.4 Hz, 1H, H-3″), 5.21 (appt. t, J = 8.7 Hz, 1H, H-3), 5.18 (dd, J = 3.4 Hz, 1H, H-2″), 5.10 (dd, J=10.8, 7.8 Hz, 1H, H-2′), 4.98 (d, J = 3.6 Hz, 1H, H-1″), 4.88 (dd, J = 9.4, 8.1 Hz, 1H, H-2), 4.73 (dd, J = 10.8, 2.6 Hz, 1H, H-3′), 4.51 (d, J = 7.7 Hz, 1H, H-1′), 4.49–4.47 (m, 2H, H-1, H-6a), 4.43 (dd, J=11.1, 6.2 Hz, 1H, H-6′a), 4.18–4.09 (m, 5H, H-5″, H-6″ab, H-6b, H-6′b), 4.01 (d, J = 2.1 Hz, 1H, H-4′), 3.91–3.88 (m, 1H, OCH), 3.79 (appt. t, J = 9.4 Hz, 1H, H-4), 3.75 (dd, J = 12.3 Hz, 1H, H-5′), 3.64 (ddd, J = 9.8, 5.2, 1.9 Hz, 1H, H-5), 3.59 (ddd, J = 9.8, 8.2, 4.5 Hz, 1H, OCH), 3.28–3.18 (m, 2H, CH2I), 2.13 (s, 3H), 2.12 (s, 3H), 2.08 (s, 3H), 2.07 (s, 3H), 2.066 (s, 6H), 2.063 (s, 3H), 2.056 (s, 3H), 2.04 (s, 3H), 1.98 ppm (s, 3H); 13C NMR (200 MHz, CDCl3): δ = 170.7, 170.5, 170.46, 170.44, 170.1, 169.8, 169.6, 169.5, 168.9, 101.1, 100.7, 99.6, 76.9, 76.4, 73.0, 72.8, 72.6, 71.8, 71.7, 69.2, 68.9, 68.8, 67.9, 67.1, 67.0, 62.1, 61.3, 60.3, 32.8, 20.94, 20.91, 20.85, 20.74, 20.72, 20.7, 20.68, 20.65, 20.60, 20.5, 3.0 ppm; HRMS (ESI-ion trap): m/z calcd for C41H57IO26+ NH4+:1110.2526 [M + NH4+]; found: 1110.2550.

3-Azidopropyl (2,3,4,6-tetra-O-acetyl-β-O-d-galactopyranosyl)-(1-4)-O-2,3,6-tri-O-acetyl-β-d-glucopyranoside (17)

NaN3 (43 mg, 0.66 mmol) was added to a dry DMF (5 mL) solution of compound 4 (180 mg, 0.22 mmol). The reaction mixture was allowed to stir at room temperature overnight. The reaction mixture was then diluted with ethyl acetate, and washed with saturated NaS2O3 (aq.) and brine. The organic layer was dried over Na2SO4 and concentrated under reduced pressure. The resulting residue was purified by using flash column chromatography (ethyl acetate/n-hexane = 50:50) to afford compound 17 (153 mg, 97% yield) as a white foam. Rf=0.25 (ethyl acetate/n-hexane = 1:1); 1H NMR (600 MHz, CDCl3): δ=5.35 (d, J = 3.0 Hz, 1H, H-4′), 5.20 (appt. t, J = 9.3 Hz, 1H, H-3), 5.11 (dd, J=10.3, 8.0 Hz, 1H, H-2′), 4.95 (dd, J = 10.4, 3.3 Hz, 1H, H-3′), 4.89 (appt. t, J = 8.8 Hz, 1H, H-2), 4.54–4.43 (m, 3H, H-1, H-1′, H-6a), 4.14–4.04 (m, 3H, H-6b, H-6′ab), 3.91 (dd, J=10.0, 5.3 Hz, 1H, OCH), 3.87 (appt. t, J = 6.8 Hz, 1H, H-5′), 3.79 (appt. t, J = 9.5 Hz, 1H, H-4), 3.66–3.52 (m, 2H, H-5, OCH), 3.35 (dt, J=11.2, 6.3 Hz, 2H, CH2N3), 2.16 (s, 3H), 2.13 (s, 3H), 2.07 (s, 3H), 2.05 (s, 9H), 1.97 (s, 3H), 1.88–1.78 ppm (m, 2H); 13C NMR(150 MHz, CDCl3): δ = 170.4, 170.1, 170.0, 169.7, 169.6, 169.1, 101.1, 100.6, 76.2, 72.7, 72.66, 72.63, 70.9, 70.7, 69.0, 66.6, 66.5, 61.9, 60.8, 47.9, 28.9, 20.8, 20.7, 20.69, 20.64, 20.62, 20.5 ppm; HRMS (ESI-ion trap): m/z calcd for C29H41N3O16 + NH4+: 737.2723 [M + NH4+];found: 737.2740.

3-Azidopropyl (β-O-d-galactopyranosyl)-(1-4)-O-β-d-glucopyranoside (18)

Compound 17 (140 mg, 0.19 mmol) was dissolved in dry MeOH (5 mL) and treated with 25% NaOMe in MeOH solution (60 μL). After 10 min, H2O (1 mL) was added to dissolve the forming white precipitate. The reaction mixture was stirred for another 1 h and was acidified to pH 6 by adding Dowex H+ resin. The solution was filtered through a plug of C18 reverse-phase silica gel and washed with MeOH and water to remove the resin and desalt. The filtrate was concentrated and lyophilized to afford compound 18 (81 mg, quantitative) as a white fluffy foam. Rf = 0.67 (ethyl acetate/MeOH/H2O=5:4:1); 1H NMR (800 MHz, MeOD): δ=4.36 (d, J=7.7 Hz, 1H, H-1′), 4.29 (d, J=7.8 Hz, 1H, H-1), 3.96 (dt, J=10.1, 6.1 Hz, 1H, OCH), 3.90 (dd, J=12.1, 2.4 Hz, 1H, H-6a), 3.86–3.83 (m, 1H, H-6b), 3.81 (d, J=4.9 Hz, 1H, H-4′), 3.77 (dt, J=14.0, 7.0 Hz, 1H, H-6′a), 3.72–3.67 (m, 1H, H-6′b), 3.64 (dt, J=10.1, 6.1 Hz, 1H, OCH), 3.61– 3.47 (m, 5H, H-3, H-4, H-2′, H-3′. H-5′), 3.47–3.43 (m, 2H, CH2N3), 3.41 (ddd, J=9.7, 4.1, 2.5 Hz, 1H, H-5), 3.25 (dd, J=9.2, 7.9 Hz, 1H, H-2), 1.90–1.84 ppm (m, 2H); 13C NMR (200 MHz, CDCl3): δ=105.1, 104.3, 80.6, 77.0, 76.4, 76.3, 74.8, 74.7, 72.6, 70.3, 70.2, 67.6, 62.5, 61.9, 30.2 ppm; HRMS (ESI-ion trap): m/z calcd for C15H27N3O11 + Na+: 448.1538 [M+Na+]; found: 448.1531.

3-Azidopropyl (2,3,4,6-Tetra-O-acetyl-α-d-galactopyranosyl)-(1-4)-O-(2,3,6-tri-O-acetyl-β-O-d-galactopyranosyl)-(1-4)-O-2,3,6-tri-O-acetyl-β-d-glucopyranoside (19)

NaN3 (59 mg, 0.9 mmol) was added to a dry DMF (5 mL) solution of compound 16 (197 mg, 0.18 mmol). The reaction mixture was allowed to stir at room temperature for 2 h. The reaction mixture was then diluted with ethyl acetate, and washed with saturated NaS2O3 (aq.) and brine. The organic layer was dried over Na2SO4 and concentrated under reduced pressure. The resulting residue was purified by using flash column chromatography (ethyl acetate/n-hexane=60:40) to afford compound 19 (167 mg, 92% yield) as a white foam. Rf =0.42 (ethyl acetate/n-hexane=2:1); 1H NMR (600 MHz, CDCl3): δ=5.53 (d, J=3.1 Hz, 1H, H-4″), 5.33 (dd, J= 11.0, 3.3 Hz, 1H, H-3″), 5.18–5.10 (m, 2H, H-3, H-2″), 5.05 (dd, J= 7.8 Hz, 1H, H-2″), 4.93 (d, J=3.6 Hz, 1H, H-1″), 4.83 (appt. t, J=8.7 Hz, 1H, H-2), 4.67 (d, J=10.8 Hz, 1H, H-3′), 4.49–4.33 (m, 5H, H-1, H-1′, H-6a, H-6′a), 4.16–3.98 (m, 5H, H-5″, H-6″ab, H-6b, H-6″b), 3.95 (s, 1H, H-4′), 3.87–3.84 (m, 1H, OCH), 3.75–3.69 (m, 2H, H-4, H-5′), 3.63–3.50 (m, 2H, H-5, OCH), 3.35–3.23 (m, 2H, CH2N3), 2.07 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 2.007 (s, 3H), 2.00 (s, 3H), 1.99 (s, 3H), 1.98 (s, 3H), 1.93 (s, 3H), 1.81–1.73 ppm (m, 2H); 13C NMR (150 MHz, CDCl3): δ=170.7, 170.5, 170.48, 170.45, 170.1, 169.8, 169.7, 169.6, 168.9, 101.1, 100.6, 99.7, 76.5, 73.1, 72.8, 72.6, 71.8, 71.7, 69.0, 68.9, 67.9, 67.2, 67.1, 66.5, 62.2, 61.8, 60.3, 48.0, 29.0, 20.9, 20.8, 20.73, 20.70, 20.66, 20.62, 20.5 ppm; HRMS (ESI-ion trap): m/z calcd for C41H57N3O26 + NH4+: 1025.3569 [M+NH4+]; found: 1025.3591.

3-Azidopropyl α-d-galactopyranosyl)-(1-4)-O-β-d-galactopyranosyl)-(1-4)-O-β-d-glucopyranoside (20)

Compound 19 (30 mg, 0.03 mmol) was dissolved in dry MeOH (1 mL) and treated with 25% NaOMe in MeOH solution (13 μL). After 10 min, H2O (1 mL) was added to dissolved the forming white precipitate. The reaction mixture was stirred for another 1 h and was acidified to pH 6 by adding Dowex H+ resin. The solution was filtered through a plug of C18 reverse-phase silica gel and washed with MeOH and water to remove the resin and desalt. The filtrate was concentrated and lyophilized to afford compound 20 (18 mg, quantitative yield) as a white fluffy foam. Rf =0.40 (ethyl acetate/MeOH/H2O=5:4:1); 1H NMR (600 MHz, D2O): δ=4.75 (d, J=4.0 Hz, 1H), 4.31 (d, J=7.8 Hz, 1H), 4.29 (d, J=8.0 Hz, 1H), 4.16 (appt. t, J=6.4 Hz, 1H), 3.87–3.82 (m, 3H), 3.82 (s, 2H), 3.76–3.67 (m, 3H), 3.67–3.61 (m, 4H), 3.61–3.47 (m, 7H), 3.47 (s, 3H), 3.42–3.34 (m, 2H), 3.26 (appt. t, J=6.7 Hz, 2H), 3.15 (s, 1H), 3.11 (appt. t, J = 8.6 Hz, 1 H), 1.77–1.71 ppm (m, 2H); 13C NMR (150 Hz, D2O): δ = 103.2, 102.0, 100.3, 78.5, 77.3, 75.4, 74.8, 74.4, 72.8, 72.1, 70.8, 70.7, 69.1, 68.9, 68.5, 67.3, 60.4, 60.3, 59.9, 47.8, 28.2, 23.2 ppm; HRMS (ESI-ion trap): m/z calcd for C21H37N3O16 + Na+: 610.2066 [M + Na+]; found: 610.2061.

Lactose click tetramer (22)

Tetraalkyne 21 (17 mg, 0.06 mmol), compound 17 (220 mg, 0.31 mmol), and TBTA ligand (25 mg, 0.05 mmol) were added to a 25 mL round-bottomed flask. The compounds were dissolved in dry DMF (1 mL), followed by the addition of an aqueous solution (0.3 mL) of CuSO4·5H2O (9 mg, 0.04 mmol) and sodium ascorbate (10 mg, 0.05 mmol). The reaction mixture was allowed to stir at room temperature in the dark for 20 h. After TLC analysis revealed the complete consumption of compound 21, the solvent was evaporated, and the resulting residue was purified by using flash column chromatography (ethyl acetate/MeOH = 15:1) to afford the protected click product. The product was then dissolved in dry MeOH (2 mL) and treated with 25% NaOMe in MeOH solution (40 μL). After 1H, the reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by using C18 reverse-phase column chromatography (MeOH/H2O = 20:80) to afford compound 22 (94 mg, 78% yield) as a white powder. C18 reverse phase Rf = 0.18 (MeOH/H2O = 1:5); 1H NMR (800 MHz, D2O): δ = 8.00–7.90 (m, 4H), 4.53–4.48 (m, 16H), 4.45 (d, J = 7.8 Hz, 4H, H-1′), 4.43 (d, J = 8.0 Hz, 4H, H-1), 3.94 (dd, J=19.5, 7.3 Hz, 4H, H-6a), 3.90–3.83 (m, 4H, H-4′), 3.83–3.70 (m, 16H, H-5, H-6b, H-6′ab), 3.68–3.62 (m, 12H, H-3, H-3′, H-5′), 3.62–3.58 (m, 4H, OCH), 3.56–3.53 (m, 8H, H-2′, H-4), 3.38 (s, 8H), 3.36–3.29 (m, 4H, H-2), 2.28–2.09 ppm (m, 8H); 13C NMR (200 MHz, D2O): δ = 143.9, 124.9, 102.8, 101.9, 78.3, 75.2, 74.6, 74.2, 72.6, 72.4, 70.8, 68.4, 67.7, 66.2, 63.3, 60.9, 59.9, 46.9, 29.4 ppm; HRMS (ESI-ion trap): m/z calcd for C79H130N12O49 + 2H+: 995.4045 [M + 2H+]; found: 995.4119.

Globotriaose click tetramer (23)

Tetraalkyne 21 (12 mg, 0.04 mmol), compound 19 (180 mg, 0.18 mmol), and TBTA ligand (17 mg, 0.03 mmol) were added to a 25 mL round-bottomed flask. The compounds were dissolved in dry DMF (1 mL), followed by the addition of an aqueous solution (0.3 mL) of CuSO4·5H2O (6 mg, 0.02 mmol) and sodium ascorbate (6 mg, 0.03 mmol). The reaction mixture was allowed to stir at room temperature in the dark for 16 h. After TLC analysis revealed the complete consumption of compound 21, the solvent was evaporated, and the resulting residue was purified by using gradient flash column chromatography (ethyl acetate/MeOH = 15:1 to 10:1) to afford the protected click product. The product was then dissolved in dry MeOH (1.5 mL) and treated with 25% NaOMe in MeOH (25 μL). After 10 min, H2O (1 mL) was added to dissolve the forming white precipitate and the reaction mixture was allowed to stir for 1 h. Next, the reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by using C18 reverse-phase column chromatography (MeOH/H2O = 1:5) to afford compound 23 (53 mg, 60% yield) as a white powder. C18 reverse phase Rf = 0.29 (MeOH/H2O = 1:5); 1H NMR (800 MHz, D2O): δ = 7.91 (s, 4H), 4.90 (d, J = 3.9 Hz, 4H, H-1″), 4.50–4.43 (m, 20 H, H-1′, CH2× 8), 4.38 (d, J = 8.0 Hz, 4H, H-1), 4.31 (appt. t, J = 6.4 Hz, 4H), 3.99 (d, J = 2.8 Hz, 4H, H-4″), 3.98 (d, J = 3.0 Hz, 4H, H-4′), 3.93–3.68 (m, 40 H, H-6ab, H-6′ab, H-3′, H-3″, H-2″, H-5′, H-5″, OCH), 3.68–3.63 (m, 8 H, H-5′, H-5″), 3.62–3.57 (m, 8 H, H-6″ab), 3.56–3.48 (m, 12 H, H-2′, H-4, OCH), 3.32 (s, 8H, CH2×4), 3.27 (appt. t, J = 8.4 Hz, 4H, H-2), 2.18–2.09 ppm (m, 8H, CH2×4). 13C NMR (200 MHz, D2O): δ = 143.9, 124.9, 103.1, 101.9, 100.1, 78.4, 77.2, 75.3, 74.6, 74.2, 72.7, 71.9, 70.7, 70.6, 68.9, 68.7, 68.4, 67.6, 66.2, 63.2, 60.3, 60.2, 59.8, 46.9, 29.4, 23.1 ppm; HRMS (ESI-ion trap): m/z calcd for C163H170N12O69 + 2H+: 1319.5101 [M + 2H+]; found: 1319.5159.

Trivalent-globobotriaose/PADRE click conjugate (25)

The procedure for synthesizing compound 25 was modified from previous publications.[32,38] To a 10 mL flame-dried round-bottomed flask was added 500 μL of compound 24 (1.4 mg) and 1.5 mL compound 20 (4.2 mg) solution. Both compounds were dissolved in degassed 100 mm PBS buffer at pH 7.4. A pre-mixed solution of CuSO4·5H2O (20 μL of 20 mm stock solution in degassed HPLC-grade H2O) and THPTA (42 μL of 50 mm stock solution in degassed HPLC-grade H2O) was added, and the reaction mixture was allowed to stir under Ar. A solution of aminoguanidine (200 μL of 100 mm stock solution in degassed HPLC-grade H2O) was also added followed by the addition of a freshly prepared solution of sodium ascorbate (200 μL of 100 mm stock solution in degassed HPLC-grade H2O). The composition of the reaction mixture is summarized in Table S1 (see the Supporting Information). The reaction mixture was allowed to stir at room temperature for 18 h. Work-up involved removal of salts by passing the mixture through Bio-gel P-10 gel (90–180 μm, exclusion limit: 1.5 kDa to 20 kDa) in 50 mm EDTA, at pH 7.4, PBS buffer. Fractions were collected and the buffer was exchanged by using C18 Sep-Pak™ in 1:1 MeCN/0.1 % aqueous formic acid (FA). The white fluffy solid 25 (4.2 mg, 75% yield) was obtained after lyophilization and was analyzed by HPLC (see the Supporting Information, Figure S2) and MALDI-HRMS (see the Supporting Information, Figure S3). HRMS (MALDI-TOF): m/z calcd for C152H250N28O70 + Na+: 3610.6756 [M + Na+]; found: 3610.6914.

Supplementary Material

SI

Acknowledgments

This work is supported by NIH R01 M090262, NSF CHE-0196482, NSF CRIF Program (CHE-9808183), NSF OSTI 97–24412 and Taiwan Ministry of Education Studying Abroad Scholarship (HWH). 400, 600, and 800 MHz NMR instruments in the UC Davis NMR Facility are supported by NSF DBIO 722538 and NIH PR1973. We would like to thank Dr. William Jewell for HRMS analysis, Dr. Jerry Dallas for help with 2D NMR experiments, and Dr. Matthew Schombs for insightful discussions. JGH also acknowledges support of the National Science Foundation for independent research development during her tenure as Division Director of Chemistry.

Footnotes

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/chem.201400024.

References

  • 1.a) Varki A, Kannagi R, Toole BP. In: Essentials of Glycobiology. 2nd. Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, editors. Cold Spring Harbor, NY: 2009. [PubMed] [Google Scholar]; b) Hakomori S. Proc Natl Acad Sci USA. 2002;99:10231–10233. doi: 10.1073/pnas.172380699. [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Hakomori S. Pure Appl Chem. 1991;63:473–482. [Google Scholar]; d) Dube DH, Bertozzi CR. Nat Rev Drug Discovery. 2005;4:477–488. doi: 10.1038/nrd1751. [DOI] [PubMed] [Google Scholar]
  • 2.a) Schmidt RR. Angew Chem. 1986;98:213–236. [Google Scholar]; Angew Chem Int Ed Engl. 1986;25:212–235. [Google Scholar]; b) Laine RA, Pamidimukkala KM, French AD, Hall RW, Abbas SA, Jain RK, Matta KL. J Am Chem Soc. 1988;110:6931–6939. [Google Scholar]
  • 3.a) National Research Council of the National Academies. Transforming Glycoscience: A Roadmap for the Future. The National Academies Press; Washington, D.C.: 2012. [PubMed] [Google Scholar]; b) Smith DF, Prieto PA. Special Considerations for Glycolipides and Their Purification. In: Varki A, Freeze HH, Manzi AE, editors. Current Protocols in Molecular Biology. Wiley; New York: 1993. pp. 17.3.1–17.3.13. [DOI] [PubMed] [Google Scholar]
  • 4.a) Seeberger PH. Chem Commun. 2003:1115–1121. doi: 10.1039/b210230g. [DOI] [PubMed] [Google Scholar]; b) Seeberger PH, Werz DB. Nature. 2007;446:1046–1051. doi: 10.1038/nature05819. [DOI] [PubMed] [Google Scholar]; c) Seeberger PH. Chem Soc Rev. 2008;37:19–28. doi: 10.1039/b511197h. [DOI] [PubMed] [Google Scholar]; d) Hsu CH, Hung SC, Wu CY, Wong CH. Angew Chem. 2011;123:12076–12129. [Google Scholar]; Angew Chem Int Ed. 2011;50:11872–11923. doi: 10.1002/anie.201100125. [DOI] [PubMed] [Google Scholar]
  • 5.a) Koeller KM, Wong CH. Chem Rev. 2000;100:4465–4493. doi: 10.1021/cr990297n. [DOI] [PubMed] [Google Scholar]; b) Zhang ZY, Ollmann IR, Ye XS, Wischnat R, Baasov T, Wong CH. J Am Chem Soc. 1999;121:734–753. [Google Scholar]; c) Hsu Y, Lu XA, Zulueta MM, Tsai CM, Lin KI, Hung SC, Wong CH. J Am Chem Soc. 2012;134:4549–4552. doi: 10.1021/ja300284x. [DOI] [PubMed] [Google Scholar]
  • 6.a) Zhang J, Kowal P, Chen X, Wang PG. Org Biomol Chem. 2003;1:3048–3053. doi: 10.1039/b304911f. [DOI] [PubMed] [Google Scholar]; b) Yao Q, Song J, Xia C, Zhang W, Wang PG. Org Lett. 2006;8:911–914. doi: 10.1021/ol053070p. [DOI] [PubMed] [Google Scholar]; c) Tsai TI, Lee HY, Chang SH, Wang CH, Tu YC, Lin YC, Hwang DR, Wu CY, Wong CH. J Am Chem Soc. 2013;135:14831–14839. doi: 10.1021/ja4075584. [DOI] [PubMed] [Google Scholar]
  • 7.Gebus C, Cottin C, Randriantsoa M, Drouillard S, Samain E. Carbohydr Res. 2012;361:83–90. doi: 10.1016/j.carres.2012.05.015. [DOI] [PubMed] [Google Scholar]
  • 8.Morales-Serna JA, Diaz Y, Matheu I, Castillon S. Eur J Org Chem. 2009:3849–3852. [Google Scholar]
  • 9.a) Fasting C, Schalley CA, Weber M, Seitz O, Hecht S, Koksch B, Dernedde J, Graf C, Knapp EW, Haag R. Angew Chem. 2012;124:10622–10650. doi: 10.1002/anie.201201114. [DOI] [PubMed] [Google Scholar]; Angew Chem Int Ed. 2012;51:10472–10498. doi: 10.1002/anie.201201114. [DOI] [PubMed] [Google Scholar]; b) Mammen M, Choi SK, Whitesides GM. Angew Chem. 1998;110:2908–2953. doi: 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]; Angew Chem Int Ed. 1998;37:2754–2794. doi: 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]; c) Branson TR, Turnbull WB. Chem Soc Rev. 2013;42:4613–4622. doi: 10.1039/c2cs35430f. [DOI] [PubMed] [Google Scholar]
  • 10.a) Fazio F, Bryan MC, Blixt O, Paulson JC, Wong CH. J Am Chem Soc. 2002;124:14397–14402. doi: 10.1021/ja020887u. [DOI] [PubMed] [Google Scholar]; b) Bryan MC, Fazio F, Lee HK, Huang CY, Chang A, Best MD, Calarese DA, Blixt O, Paulson JC, Burton D, Wilson IA, Wong CH. J Am Chem Soc. 2004;126:8640–8641. doi: 10.1021/ja048433f. [DOI] [PubMed] [Google Scholar]; c) Horlacher T, Seeberger PH. Chem Soc Rev. 2008;37:1414–1422. doi: 10.1039/b708016f. [DOI] [PubMed] [Google Scholar]; d) Hung TC, Lin CW, Hsu TL, Wu CY, Wong CH. J Am Chem Soc. 2013;135:5934–5937. doi: 10.1021/ja312210c. [DOI] [PubMed] [Google Scholar]
  • 11.a) Slovin SF, Keding SJ, Ragupathi G. Immunol Cell Biol. 2005;83:418–428. doi: 10.1111/j.1440-1711.2005.01350.x. [DOI] [PubMed] [Google Scholar]; b) Wilson RM, Danishefsky SJ. J Am Chem Soc. 2013;135:14462–14472. doi: 10.1021/ja405932r. [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Shiao TC, Roy R. New J Chem. 2012;36:324–339. [Google Scholar]; d) Astronomo RD, Burton DR. Nat Rev Drug Discovery. 2010;9:308–324. doi: 10.1038/nrd3012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.a) Zhu X, Schmidt RR. Angew Chem. 2009;121:1932–1967. [Google Scholar]; Angew Chem. 2009;48:1900–1934. doi: 10.1002/anie.200802036. [DOI] [PubMed] [Google Scholar]; b) Galonic DP, Gin DY. Nature. 2007;446:1000–1007. doi: 10.1038/nature05813. [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Ranade SC, Demchenko AV. J Carbohydr Chem. 2013;32:1–43. [Google Scholar]
  • 13.a) El-Badri MH, Willenbring D, Tantillo DJ, Gervay-Hague J. J Org Chem. 2007;72:4663–4672. doi: 10.1021/jo070229y. [DOI] [PubMed] [Google Scholar]; b) Dabideen DR, Gervay-Hague J. Org Lett. 2004;6:973–975. doi: 10.1021/ol049966w. [DOI] [PubMed] [Google Scholar]; c) El-Badry MH, Gervay-Hague J. Tetrahedron Lett. 2005;46:6727–6728. [Google Scholar]
  • 14.a) Guillemineau M, Auzanneau FI. J Org Chem. 2012;77:8864–8878. doi: 10.1021/jo301644w. [DOI] [PubMed] [Google Scholar]; b) Oberli MA, Bindschadler P, Werz DB, Seeberger PH. Org Lett. 2008;10:905–908. doi: 10.1021/ol7030262. [DOI] [PubMed] [Google Scholar]; c) Verley A, Bölsing F. Ber Dtsch Chem Ges. 1901;34:3354–3358. [Google Scholar]; d) Höfle G, Steglich W, Vorbruggen H. Angew Chem. 1978;90:602–615. [Google Scholar]; Angew Chem Int Ed Engl. 1978;17:569–583. [Google Scholar]
  • 15.a) Mukhopadhyay B, Kartha KPR, Russell DA, Field RA. J Org Chem. 2004;69:7758–7760. doi: 10.1021/jo048890e. [DOI] [PubMed] [Google Scholar]; b) Bickley J, Cottrell JA, Ferguson JR, Field RA, Harding JR, Hughes DL, Kartha KPR, Law JL, Scheinmann F, Stachulski AV. Chem Commun. 2003:1266–1267. doi: 10.1039/b302629a. [DOI] [PubMed] [Google Scholar]
  • 16.a) Fraser-Reid B, Wu ZF, Udodong UE, Ottosson H. J Org Chem. 1990;55:6068–6070. [Google Scholar]; b) Fraser-Reid B, Lopez JC. In: Reactivity Tuning in Oligosaccharide Assembly. Fraser-Reid B, Cristobal Lopez J, editors. Vol. 301. Springer Berlin; Heidelberg: 2011. pp. 1–29. [Google Scholar]
  • 17.Perrie JA, Harding JR, King C, Sinnott D, Stachulski AV. Org Lett. 2003;5:4545–4548. doi: 10.1021/ol035475k. [DOI] [PubMed] [Google Scholar]
  • 18.a) Morales-Serna JA, Boutureira O, Diaz Y, Matheu MI, Castillon S. Org Biomol Chem. 2008;6:443–446. doi: 10.1039/b718521a. [DOI] [PubMed] [Google Scholar]; b) Morales-Serna JA, Diaz Y, Matheu MI, Castillon S. Org Biomol Chem. 2008;6:3831–3836. doi: 10.1039/b809570a. [DOI] [PubMed] [Google Scholar]
  • 19.a) Kartha KPR, Aloui M, Field RA. Tetrahedron Lett. 1996;37:8807–8810. [Google Scholar]; b) van Well RM, Ravindranathan Kartha KP, Field RA. J Carbohydr Chem. 2005;24:463–474. [Google Scholar]
  • 20.a) Murakami T, Hirono R, Sato Y, Furusawa K. Carbohydr Res. 2007;342:1009–1020. doi: 10.1016/j.carres.2007.02.024. [DOI] [PubMed] [Google Scholar]; b) Murakami T, Sato Y, Shibakami M. Carbohydr Res. 2008;343:1297–1308. doi: 10.1016/j.carres.2008.03.019. [DOI] [PubMed] [Google Scholar]
  • 21.a) Bhat AS, Gervay-Hague J. Org Lett. 2001;3:2081–2084. doi: 10.1021/ol0160405. [DOI] [PubMed] [Google Scholar]; b) Kulkarni SS, Gervay-Hague J. Org Lett. 2006;8:5765–5768. doi: 10.1021/ol062354m. [DOI] [PubMed] [Google Scholar]; c) Kulkarni SS, Gervay-Hague J. Org Lett. 2008;10:4739–4742. doi: 10.1021/ol801780c. [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Du W, Kulkarni SS, Gervay-Hague J. Chem Commun. 2007:2336–2338. doi: 10.1039/b702551c. [DOI] [PubMed] [Google Scholar]; e) Schombs M, Park FE, Du WJ, Kulkarni SS, Gervay-Hague J. J Org Chem. 2010;75:4891–4898. doi: 10.1021/jo100366v. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.a) Hsieh HW, Schombs MW, Witschi MA, Gervay-Hague J. J Org Chem. 2013;78:9677–9688. doi: 10.1021/jo4013805. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Hsieh HW, Schombs MW, Gervay-Hague J. J Org Chem. 2014;79:1736–1748. doi: 10.1021/jo402736g. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Witschi MA, Gervay-Hague J. Org Lett. 2010;12:4312–4315. doi: 10.1021/ol101751d. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Davis RA. PhD Dissertation. University of California; Davis (Davis, CA): 2012. [Google Scholar]
  • 25.Li L, Xu Y, Milligan I, Fu L, Franckowiak EA, Du W. Angew Chem. 2013;125:13944–13947. doi: 10.1002/anie.201306391. [DOI] [PubMed] [Google Scholar]
  • 26.Bochkov AF, Betaneli VI, Kochetkov NK. Russ Chem Bull. 1974;23:1299–1304. [Google Scholar]
  • 27.a) Kappe CO. Angew Chem. 2004;116:6408–6443. [Google Scholar]; Angew Chem Int Ed. 2004;43:6250–6284. doi: 10.1002/anie.200400655. [DOI] [PubMed] [Google Scholar]; b) Kappe CO, Pieber B, Dallinger D. Angew Chem. 2013;125:1124–1130. doi: 10.1002/anie.201204103. [DOI] [PubMed] [Google Scholar]; Angew Chem Int Ed. 2013;52:1088–1094. doi: 10.1002/anie.201204103. [DOI] [PubMed] [Google Scholar]
  • 28.Kaeothip S, Yasomanee JP, Demchenko AV. J Org Chem. 2012;76:291–299. doi: 10.1021/jo2019174. [DOI] [PubMed] [Google Scholar]
  • 29.Pryor WA, Gu J, Church DF. J Org Chem. 1985;50:185–189. [Google Scholar]
  • 30.Gervay J, Nguyen TN, Hadd MJ. Carbohydr Res. 1997;300:119–125. [Google Scholar]
  • 31.Hein JE, Fokin VV. Chem Soc Rev. 2010;39:1302–1315. doi: 10.1039/b904091a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.a) Schellinger JG, Danan-Leon LM, Hoch JA, Kassa A, Srivastava I, Davis D, Gervay-Hague J. J Am Chem Soc. 2011;133:3230–3233. doi: 10.1021/ja1083915. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Natarajan A, Du W, Xiong CY, DeNardo GL, DeNardo SJ, Gervay-Hague J. Chem Commun. 2007:695–697. doi: 10.1039/b611636a. [DOI] [PubMed] [Google Scholar]
  • 33.a) Donnelly PS, Zanatta SD, Zammit SC, White JM, Williams SJ. Chem Commun. 2008:2459–2461. doi: 10.1039/b719724a. [DOI] [PubMed] [Google Scholar]; b) Chan TR, Hilgraf R, Sharpless KB, Fokin VV. Org Lett. 2004;6:2853–2855. doi: 10.1021/ol0493094. [DOI] [PubMed] [Google Scholar]
  • 34.Schellinger JG, Kudupudi A, Natarajan A, Du WJ, DeNardo SJ, Gervay-Hague J. Org Biomol Chem. 2012;10:1521–1526. doi: 10.1039/c0ob01259a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Alexander J, Fikes J, Hoffman S, Franke E, Sacci J, Appella E, Chisari F, Guidotti L, Chesnut R, Livingston B, Sette A. Immunol Res. 1998;18:79–92. doi: 10.1007/BF02788751. [DOI] [PubMed] [Google Scholar]
  • 36.a) Galan MC, Dumy P, Renaudet O. Chem Soc Rev. 2013;42:4599–4612. doi: 10.1039/c2cs35413f. [DOI] [PubMed] [Google Scholar]; b) Renaudet O, BenMohamed L, Dasgupta G, Bettahi I, Dumy P. ChemMedChem. 2008;3:737–741. doi: 10.1002/cmdc.200700315. [DOI] [PubMed] [Google Scholar]
  • 37.a) Peri F. Chem Soc Rev. 2013;42:4543–4556. doi: 10.1039/c2cs35422e. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Adamo R, Nilo A, Castagner B, Boutureira O, Berti F, Bernardes GJL. Chem Sci. 2013;4:2995–3008. doi: 10.1039/c3sc50862e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Hong V, Presolski SI, Ma C, Finn MG. Angew Chem. 2009;121:10063–10067. doi: 10.1002/anie.200905087. [DOI] [PMC free article] [PubMed] [Google Scholar]; Angew Chem Int Ed. 2009;48:9879–9883. doi: 10.1002/anie.200905087. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

SI

RESOURCES